U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H15N.ClH
Molecular Weight 245.747
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CENTANAFADINE HYDROCHLORIDE

SMILES

Cl.[H][C@]12C[C@]1(CNC2)C3=CC4=C(C=CC=C4)C=C3

InChI

InChIKey=ACVMJAJGCQUPKX-LIOBNPLQSA-N
InChI=1S/C15H15N.ClH/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15;/h1-7,14,16H,8-10H2;1H/t14-,15+;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H15N
Molecular Weight 209.2863
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Centanafadine is an oral triple reuptake inhibitor that has been developed by DOV Pharmaceutical as a treatment for attention-deficit hyperactivity disorder (ADHD). Centanafadine works by modulating the activity of norepinephrine, dopamine, and serotonin, three neurotransmitters known to be relevant in patients with ADHD. In the human abuse liability study, immediate-release centanafadine demonstrated a reduced abuse potential compared with the schedule II stimulants d-amphetamine and lisdexamfetamine. Treatment with high doses of immediate-release centanafadine resulted in a markedly different profile than that of the comparators, with most subjects experiencing the acute onset of adverse effects, including nausea, vomiting, and dysphoria. Almost 2 hours after the administration of centanafadine, the test subjects reported “liking” at about two-thirds of the magnitude of amphetamines, a finding that may have indicated dopamine activity. However, unlike amphetamines, which provided an immediate positive experience, the subjects receiving centanafadine experienced negative effects before reaching that point.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
2012 Jun
Patents

Patents

Sample Use Guides

200 mg, BID (400 mg total daily dose)
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:27:08 GMT 2023
Edited
by admin
on Sat Dec 16 08:27:08 GMT 2023
Record UNII
265DN9X85W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CENTANAFADINE HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
CENTANAFADINE HYDROCHLORIDE, (+)-
Common Name English
EB-1020 HYDROCHLORIDE
Code English
DOV-216419 HYDROCHLORIDE
Code English
CENTANAFADINE HYDROCHLORIDE [USAN]
Common Name English
DOV 216,419 HYDROCHLORIDE
Code English
3-AZABICYCLO(3.1.0)HEXANE, 1-(2-NAPHTHALENYL)-, HYDROCHLORIDE (1:1), (1R,5S)-
Systematic Name English
(1R,5S)-1-(Naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Systematic Name English
Centanafadine hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
265DN9X85W
Created by admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
PRIMARY
USAN
AB-16
Created by admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
PRIMARY
ChEMBL
CHEMBL3301621
Created by admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
PRIMARY
PUBCHEM
68943792
Created by admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
PRIMARY
SMS_ID
300000024927
Created by admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
PRIMARY
NCI_THESAURUS
C166543
Created by admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
PRIMARY
CAS
923981-14-0
Created by admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY